Veronica Mollica

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 33

Top Topics

Ejection Fraction

Renal Cell Carcinoma

Top Venues

Future oncology (London, England)

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Costantino Ricci, Francesca Ambrosi, Alessia Grillini, Marco Grillini, Veronica Mollica, Michelangelo Fiorentino, Ankur R Sangoi, Antonio De Leo, Muhammad T Idrees, Thomas M Ulbright, Andres Martin Acosta
Immunophenotypical assessment supports that post-chemotherapy glandular tumours of germ cell origin straddle between glandular yolk sac tumour and 'somatic-type' adenocarcinoma. Histopathology 85 (4) (2024)
Costantino Ricci, Francesca Ambrosi, Alessia Grillini, Marco Grillini, Veronica Mollica, Michelangelo Fiorentino, Ankur R Sangoi, Antonio De Leo, Muhammad T Idrees, Thomas M Ulbright, Andres Martin Acosta
Immunophenotypical assessment supports that post-chemotherapy glandular tumours of germ cell origin straddle between glandular yolk sac tumour and 'somatic-type' adenocarcinoma. Histopathology (2024)
Costantino Ricci, Francesca Ambrosi, Alessia Grillini, Marco Grillini, Veronica Mollica, Michelangelo Fiorentino, Ankur R Sangoi, Antonio De Leo, Muhammad T Idrees, Thomas M Ulbright, Andres Martin Acosta
Immunophenotypical assessment supports that post-chemotherapy glandular tumours of germ cell origin straddle between glandular yolk sac tumour and 'somatic-type' adenocarcinoma. Histopathology 85 (4) (2024)
Luisa Di Sciascio, Agnese Orsatti, Francesca Ambrosi, Eugenia Franchini, Francesco Massari, Veronica Mollica, Federico Mineo Bianchi, Maurizio Colecchia, Antonio De Leo, Andres Martin Acosta, João Lobo, Michelangelo Fiorentino, Costantino Ricci
Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel. Virchows Archiv : an international journal of pathology (2024)
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, Francesco Massari, Razelle Kurzrock, Jacob J Adashek
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Alessandro Rizzo, Giacomo Nuvola, Gennaro Palmiotti, Selma Ahcene-Djaballah, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Maria Concetta Nigro, Elisa Tassinari, Sveva Macrini, Francesco Massari
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy 15 (2) (2023)
Thais Maloberti, Antonio De Leo, Sara Coluccelli, Viviana Sanza, Elisa Gruppioni, Annalisa Altimari, Stefano Zagnoni, Francesca Giunchi, Francesco Vasuri, Michelangelo Fiorentino, Veronica Mollica, Simona Ferrari, Sara Miccoli, Michela Visani, Daniela Turchetti, Francesco Massari, Giovanni Tallini, Dario de Biase
Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1 / BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer. International journal of molecular sciences 24 (10) (2023)
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, Francesco Massari, Razelle Kurzrock, Jacob J Adashek
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Alessandro Rizzo, Giacomo Nuvola, Gennaro Palmiotti, Selma Ahcene-Djaballah, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Maria Concetta Nigro, Elisa Tassinari, Sveva Macrini, Francesco Massari
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy 15 (2) (2023)
Costantino Ricci, Francesca Ambrosi, Tania Franceschini, Francesca Giunchi, Giorgia Di Filippo, Eugenia Franchini, Francesco Massari, Veronica Mollica, Valentina Tateo, Federico Mineo Bianchi, Maurizio Colecchia, Andres Martin Acosta, Michelangelo Fiorentino
FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type. Histopathology (2023)
Alessandro Rizzo, Giacomo Nuvola, Gennaro Palmiotti, Selma Ahcene-Djaballah, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Maria Concetta Nigro, Elisa Tassinari, Sveva Macrini, Francesco Massari
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy 15 (2) (2023)
Giacomo Nuvola, Veronica Mollica, Francesco Massari, Cristina Suárez
The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors. Immunotherapy (2023)
Costantino Ricci, Francesca Ambrosi, Tania Franceschini, Francesca Giunchi, Alessia Grillini, Eugenia Franchini, Marco Grillini, Riccardo Schiavina, Francesco Massari, Veronica Mollica, Valentina Tateo, Federico Mineo Bianchi, Lorenzo Bianchi, Matteo Droghetti, Thais Maloberti, Giovanni Tallini, Maurizio Colecchia, Andres Martin Acosta, João Lobo, Kiril Trpkov, Michelangelo Fiorentino, Dario de Biase
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT. Virchows Archiv : an international journal of pathology (2023)
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, Francesco Massari, Razelle Kurzrock, Jacob J Adashek
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Alessandro Rizzo, Giacomo Nuvola, Gennaro Palmiotti, Selma Ahcene-Djaballah, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Maria Concetta Nigro, Elisa Tassinari, Sveva Macrini, Francesco Massari
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy (2023)
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, Francesco Massari, Razelle Kurzrock, Jacob J Adashek
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Giacomo Nuvola, Alessandro Rizzo, Veronica Mollica, Francesco Massari
The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: will immunotherapy solve the problem? Immunotherapy 14 (4) (2022)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola, Rodolfo Montironi, Francesco Massari
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Future oncology (London, England) 18 (6) (2022)
Matteo Righini, Veronica Mollica, Alessandro Rizzo, Gaetano La Manna, Francesco Massari
Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. Journal of clinical medicine 11 (15) (2022)
Matteo Santoni, Francesco Massari, Alessandro Rizzo, Veronica Mollica, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis. Tumori (2022)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Gennaro Palmiotti, Francesco Massari
Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis. Journal of clinical medicine 11 (4) (2022)
Emanuel Raschi, Michele Fusaroli, Francesco Massari, Veronica Mollica, Andrea Repaci, Andrea Ardizzoni, Elisabetta Poluzzi, Uberto Pagotto, Guido Di Dalmazi
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System. The Journal of clinical endocrinology and metabolism 107 (8) (2022)
Sara Elena Rebuzzi, Pasquale Rescigno, Fabio Catalano, Veronica Mollica, Ursula Maria Vogl, Laura Marandino, Francesco Massari, Ricardo Pereira Mestre, Elisa Zanardi, Alessio Signori, Sebastiano Buti, Matteo Bauckneht, Silke Gillessen Sommer, Giuseppe Luigi Banna, Giuseppe Fornarini
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. Cancers 14 (5) (2022)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Francesco Massari
Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer. Journal of clinical medicine 11 (21) (2022)
Alessandro Rizzo, Matteo Santoni, Veronica Mollica, Angela Dalia Ricci, Concetta Calabrò, Antonio Cusmai, Gennaro Gadaleta-Caldarola, Gennaro Palmiotti, Francesco Massari
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis. Journal of personalized medicine 12 (5) (2022)
Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, Giacomo Nuvola, Matteo Rosellini, Elisa Tassinari, Javier Molina-Cerrillo, Zin W Myint, Tomas Buchler, Fernando Sabino Marques Monteiro, Enrique Grande, Matteo Santoni, Francesco Massari
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. Cancers 14 (17) (2022)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Francesco Massari
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysis. Immunotherapy 14 (8) (2022)
Costantino Ricci, Tania Franceschini, Francesca Giunchi, Marco Grillini, Francesca Ambrosi, Francesco Massari, Veronica Mollica, Maurizio Colecchia, Michelangelo Fiorentino
Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia in Situ, and Germ Cell Tumors of the Testis. American journal of clinical pathology (2021)
Alessandro Rizzo, Veronica Mollica, Filippo Gustavo Dall'Olio, Angela Dalia Ricci, Ilaria Maggio, Andrea Marchetti, Matteo Rosellini, Matteo Santoni, Andrea Ardizzoni, Francesco Massari
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review. Future oncology (London, England) 17 (20) (2021)
Francesco Massari, Alessandro Rizzo, Veronica Mollica, Matteo Santoni
A brand-new CAR for macrophages: is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? Future oncology (London, England) 17 (15) (2021)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Matteo Rosellini, Andrea Marchetti, Francesco Massari
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials. Future oncology (London, England) 18 (5) (2021)
Alessandro Rizzo, Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Francesco Massari
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. Immunotherapy 13 (8) (2021)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Matteo Rosellini, Andrea Marchetti, Angela Dalia Ricci, Giada Grilli, Alba Greco, Rodolfo Montironi, Andrea Ardizzoni, Francesco Massari
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy 13 (9) (2021)